# Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

> **NCT01871766** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 115 (actual)

## Conditions studied

- Rhabdomyosarcoma

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Dactinomycin
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Surgical Resection
- **PROCEDURE:** Radiation
- **DRUG:** Bevacizumab
- **DRUG:** Sorafenib
- **DRUG:** Myeloid Growth Factor
- **PROCEDURE:** Lymph Node Sampling
- **DRUG:** Irinotecan
- **DRUG:** Ifosfamide
- **DRUG:** Etoposide
- **DRUG:** Etoposide Phosphate
- **DRUG:** Doxorubicin
- **DRUG:** Dexrazoxane
- **DRUG:** ^1^1C-methionine

## Key facts

- **NCT ID:** NCT01871766
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-12-04
- **Primary completion:** 2026-12
- **Final completion:** 2030-06
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01871766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01871766, "Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01871766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*